Search results for: Pricing and Reimbursement
Filter search results
Value-Based Pricing: OHE Comments
23 March 2011
…its comments and made the full text of its remarks available here. Briefly stated, key issues addressed in our response include the following. 1. Value-based pricing (VBP) can, and should,…
A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
19 May 2023
…antibiotics that could inform longer-term financing and reimbursement arrangements and guide prescribing behaviours. Key takeaways Antimicrobial resistance (AMR) threatens our ability to treat common infections, and antibiotic stewardship is critical…
The CBO Doesn’t Understand Investors
13 September 2021
…the CBO model investment decisions? The CBO has released three estimates of the potential impact of H.R. 3 and H.R. 3-style price caps on investment in pharmaceutical research and development…
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
…co-authored by OHE’s Adrian Towse, and the ARMoR model utilised input from OHE’s Grace Hampson, and is based on work by Adrian Towse and Rachel Silverman-Bonnifield. Anderson et al. propose…
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
22 September 2025
…validation of novel biomarkers and the development of AI-driven diagnostic tools. The consortium brings together experts and institutions from Finland, Germany, Italy, Lithuania, Luxembourg, the Netherlands, Spain, and the United…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…diversity of public and private partners. 3. Approval, pricing and financing regimes must change to realize the promise of the new science. Regulatory bodies need both personnel and procedures capable…
OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
6 August 2013
…Three countries were explored in greater depth: Kenya, South Africa and Vietnam. Although HTA could be crucial to solving the challenges of limited resources and substantial demand in LMICs, awareness…
Does the New CBO Report Change Anything?
15 September 2021
…heterogeneity in the impact across therapeutic areas, no account for how science and therefore the cost and risk of R&D has changed, and no measure of the impact on the…
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
1 August 2011
…which value based pricing might be operationalised, categorise these by developing a taxonomy of approaches, and provide an initial assessment of the challenges, pros and cons of each. They review…